Default company panoramic image
8a88aec3 421c 4203 9b3e a9cd9828d138

20/20 GeneSystems, Inc

20/20 GeneSystems commercializes innovative biomarker tests to detect early stage cancer & to personalize targeted cancer therapies.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Rockville, MD, USA
  • Currency USD
  • Founded October 2001
  • Employees 18
  • Website 2020gene.com

Company Summary

In 2012 we launched a blood test for the early detection of lung cancer. Primary care physicians draw blood samples from patients at risk for the disease due to smoking history and send the sample to our lab. We report a biomarker based risk assessment so that the higher risk patients are followed up with a CT scan. In 2013 and 2014 we plan to launch tests to predict the response of kidney and breast tumors to approved targeted therapies.

Team

  • Default avatar
    Jonathan Cohen
    President & CEO

    Mr. Cohen, founding CEO of 20/20 GeneSystems has lead the company to raise over $6M in equity investments, launch two innovative detection products, procure over $7M in funding from govt & corporate sources, & forge agreements w/ several Fortune 500 companies. Previously Mr. Cohen was patent and general counsel for 2 publicly traded companies: Ventana Medical Systems & Oncor Mr. Cohen is a registed patent attorney with over 18 years experience.

  • Default avatar
    Gerard "Jerry" Troy
    VP, Operations & Finance

    Since 2001, manages company’s BioCheck product manufacturing, packaging & distribution operations. Heads up company’s finance operation and oversees 20/20′s accounting and investor relations. Jerry is an accountant with over 25 years in the financial planning & analysis of diagnostics & biotech companies. Spent 13 years at Becton-Dickenson (BD) including Financial Manager of Diagnostics Instruments Systems Div. & the Advanced Diagnostic Div.

  • Default avatar
    Peter Tunon
    Head, Business Development

    Mr. Tunon has worked with some of the world’s largest life science suppliers. After studying biochemistry at Uppsala University, Sweden, he worked in technical support for Pharmacia (now GE Healthcare). Mr. Tunon was Business Director at Life Technologies for the downstream processing program. As Chromatography Business Manager at Bio-Rad Labs he managed the consumables program. Prior to joining 20/20 he was VP Sales & Marketing at Expression Pa

  • Default avatar
    John Gillespie, M.D.
    Director, Medical Affairs

    Joined 20/20 in late 2009. Educated and trained at the George Washington University Hospital in anatomic and clinical pathology. He then joined the Pathogenetics Unit of the National Cancer Institute where he was involved with development of laser capture microdissection & made contributions toward development of other technologies for molecular analysis of cancer tissue samples. He received several technology transfer awards for his efforts.

Advisors

  • Default avatar
    Shulman, Rogers, Gandal, Pordy & Ecker, P.A.
    Lawyer
    Unconfirmed
    Default avatar
    Snyder Cohn
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Institutional and Individual Investors
    Unconfirmed
    Default avatar
    Corporate Partnerships
    Unconfirmed
    Default avatar
    Government (federal & State)
    Unconfirmed